 The FDA has signed off Avidity Biosciences Incs NASDAQ: RNA Phase 12 MARINA trial of AOC 1001 in adults with myotonic dystrophy type 1 DM1. Myotonic dystrophy is characterized by progressive muscle wasting and weakness. 